<p><strong>通过高压波形和</strong> <strong>高效逐点脉冲场消融展示瞬时消融</strong></p>
<p>, /PRNewswire/ -- Field Medical, Inc.是一家临床阶段的医疗技术公司，致力于为复杂心脏心律失常提供脉冲场消融（PFA）解决方案，今天宣布在 2026 年第 31 届国际房颤研讨会上展示首个人体试验 Field PULSE 研究的最新临床试验数据，该会议于 2 月 5 日至 7 日在波士顿举行。</p>
<p>继续阅读</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.prnewswire.com/news-releases/null?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.prnewswire.com/news-releases/null"/></p>
<p>Field Medical 的 FieldForce™消融系统。一个聚焦的 PFA 系统，旨在支持复杂心脏心律失常的全层病灶创建。</p>
<p>Field PULSE 评估了一种新型高压、亚秒脉冲场波形，通过 Field Medical 的 FieldForce™消融系统和导管传递，这是一种聚焦的接触感应导管，能够通过逐点能量传递实现瞬时消融，而无需依赖于长时间的组织 - 导管接触。该研究被选为最新临床试验（LBCT）展示。</p>
<p>“通过消除对持续组织 - 导管接触的需求，亚秒脉冲场传递实现了高效的逐点消融和个性化的病灶设置，” Field PULSE 的首席研究员、纽约西奈山医院的心电生理学家 Vivek Y. Reddy 博士说。“这种方法保留了医生对聚焦消融的灵活性，同时提供了与脉冲场技术相关的程序效率。”</p>
<p><strong>研究亮点</strong></p>
<ul>
<li><strong>瞬时能量传递：</strong> 病灶在不到 200 毫秒内创建，实现快速逐点消融</li>
<li><strong>程序效率：</strong> 双侧肺静脉隔离（PVI）中位时间为 12.5 分钟，最快病例在 7.7 分钟内完成</li>
<li><strong>PVI 耐久性：</strong> 重新映射显示优化波形下 PVI 耐久性逐步改善</li>
</ul>
<ul>
<li><strong>按静脉计算：</strong> 94.2%
<ul>
<li><strong>按患者计算：</strong> 84.6%</li>
</ul>
</li>
</ul>
<ul>
<li><strong>安全结果：</strong></li>
</ul>
<ul>
<li>无设备相关的严重不良事件
<ul>
<li>无急性肾损伤、报告的膈神经麻痹或临床相关的溶血</li>
<li>在接受脑 MRI 评估的患者中（n=14），未观察到无症状脑病灶（DWI+/FLAIR+）</li>
</ul>
</li>
</ul>
<p>这些发现扩展了 Field Medical 在高压聚焦 PFA 方法方面的临床证据，超越了心室心律失常，进入了房颤（AF）治疗的发展。结合之前报告的六个月首个人体心室心动过速（VT）数据，这些结果支持了一个多功能消融平台的出现，旨在实现心房和心室基质的聚焦 PFA，同时保持程序效率。</p>
<p>“Field PULSE 的结果强化了我们有意设计聚焦 PFA 以解决现有方法的基本局限性，然后通过数据验证其应用的思路，” Field Medical 的创始人兼首席技术官 Steven Mickelsen 博士说。“通过在瞬间传递每个消融点，我们减少了对长时间导管稳定性的依赖，限制了心脏运动的影响，并建立了治疗复杂心律失常的平台方法。”</p>
<p>Field PULSE 数据在 2026 年 AF 研讨会的最新临床试验会议 I 上进行了展示。Field Medical 将在 2 月 6 日星期五上午 7:30 至 8:30 的科学会议上介绍脉冲场消融（PFA）在房颤中的生物物理学，包括 Kenneth Ellenbogen 博士的题为《利用高压 PFA 波形最大化病灶深度》的演讲，并在 2 月 7 日星期六上午 7:30 至 9:30 的病例传输会议 6 上，突出 Vivek Reddy 博士使用 FieldForce 消融系统和 FieldForce 消融导管进行的《使用高压 Field Medical PFA 导管进行房颤消融》的演讲。</p>
<p><strong>关于 FieldForce™消融系统</strong> FieldForce 消融系统是一种聚焦的接触感应 PFA 系统，基于专有的 FieldBending™技术，旨在通过新颖的脉冲能量传递策略提供针对性的高强度电场。该系统旨在支持心房和心室消融，作为心脏及其他部位的通用消融平台。FieldForce 系统旨在实现针对性和个性化的消融治疗，同时平台特性专注于程序效率。</p>
<p><strong>关于 Field Medical®, Inc.</strong></p>
<p>Field Medical 成立于 2022 年，由 Steven Mickelsen 博士创立，是一家临床阶段的医疗技术公司，致力于推进复杂心脏心律失常的脉冲场消融（PFA）解决方案。其 FieldForce 消融系统将聚焦导管设计与专有的 FieldBending 能量相结合，旨在安全高效地提供精确消融，以改善心室和心房心律失常治疗的结果。2024 年，Field Medical 获得突破性设备认证，并进入 FDA TAP 试点计划，针对其心室心动过速适应症。2025 年 10 月，VCAS 试验在 <strong><em>Circulation</em></strong> 上发表。</p>
<p>欲了解更多信息，请访问 www.fieldmedicalinc.com，并在 LinkedIn、X 和 YouTube 上关注我们。</p>
<p>FieldForce™消融系统是一种研究性设备，受美国联邦法律限制，仅供研究使用。</p>
<p><strong>媒体联系人</strong> Holly Windler</p>
<p>619.929.1275</p>
<p>[email protected]</p>
<p>[email protected]</p>
<p>来源 Field Medical, Inc.</p>
<p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwMjA1Jk5ld3NJdGVtSWQ9TEE4MDk2NyZUcmFuc21pc3Npb25fSWQ9MjAyNjAyMDUxNzQwUFJfTkVXU19VU1BSX19fX19MQTgwOTY3?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwMjA1Jk5ld3NJdGVtSWQ9TEE4MDk2NyZUcmFuc21pc3Npb25fSWQ9MjAyNjAyMDUxNzQwUFJfTkVXU19VU1BSX19fX19MQTgwOTY3"/></p>

Merit医疗系统

<p>Field Medical, Inc. 在 2026 年 AF Symposium 上展示了其 Field PULSE 试验的最新数据，展示了其 FieldForce™消融系统用于治疗复杂的心脏心律失常。试验表明，使用高电压波形进行瞬时消融，达到肺静脉隔离的中位时间为 12.5 分钟。结果显示没有严重不良事件，并且消融病灶的持久性得到了改善。这些数据支持了 Field Medical 的 PFA 平台在房性和室性心律失常中的多功能性，强调了心脏治疗中的程序效率和安全性</p>

<p><strong>Demonstrating Instantaneous Ablation Through High-Voltage Waveforms and</strong> <strong>Efficient Point-by-Point Pulsed Field Ablation</strong></p>
<div class="lb-trans"><p><strong>通过高压波形和</strong> <strong>高效逐点脉冲场消融展示瞬时消融</strong></p>
</div><p>, /PRNewswire/ -- Field Medical, Inc., a clinical-stage medical technology company advancing pulsed field ablation (PFA) solutions for complex cardiac arrhythmias, today announced the presentation of late breaking clinical trial data from the first-in-human Field PULSE study at the 31st Annual International AF Symposium 2026, held February 5–7 in Boston.</p>
<div class="lb-trans"><p>, /PRNewswire/ -- Field Medical, Inc.是一家临床阶段的医疗技术公司，致力于为复杂心脏心律失常提供脉冲场消融（PFA）解决方案，今天宣布在 2026 年第 31 届国际房颤研讨会上展示首个人体试验 Field PULSE 研究的最新临床试验数据，该会议于 2 月 5 日至 7 日在波士顿举行。</p>
</div><p>Continue Reading</p>
<div class="lb-trans"><p>继续阅读</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.prnewswire.com/news-releases/null" alt="" original-src="https://www.prnewswire.com/news-releases/null"/></p>
<p>The FieldForce™ Ablation System by Field Medical. A focal PFA system designed to support transmural lesion creation for complex cardiac arrhythmias.</p>
<div class="lb-trans"><p>Field Medical 的 FieldForce™消融系统。一个聚焦的 PFA 系统，旨在支持复杂心脏心律失常的全层病灶创建。</p>
</div><p>Field PULSE evaluates a novel high-voltage, sub-second pulsed field waveform delivered through Field Medical's FieldForce™ Ablation System and Catheter, a focal, contact-sensing catheter, enabling instantaneous ablation through point-by-point energy delivery without reliance on prolonged tissue-catheter contact. The study was selected for a Late Breaking Clinical Trial (LBCT) presentation.</p>
<div class="lb-trans"><p>Field PULSE 评估了一种新型高压、亚秒脉冲场波形，通过 Field Medical 的 FieldForce™消融系统和导管传递，这是一种聚焦的接触感应导管，能够通过逐点能量传递实现瞬时消融，而无需依赖于长时间的组织 - 导管接触。该研究被选为最新临床试验（LBCT）展示。</p>
</div><p>&#34;By eliminating the need for sustained tissue-catheter contact, sub-second pulsed field delivery enables both efficient point-by-point ablation and individualized lesion sets,&#34; said Vivek Y. Reddy, M.D., principal investigator of Field PULSE and electrophysiologist at Mount Sinai, New York. &#34;This approach preserves the flexibility physicians expect from focal ablation while delivering the procedural efficiency associated with pulsed field technologies.&#34;</p>
<div class="lb-trans"><p>“通过消除对持续组织 - 导管接触的需求，亚秒脉冲场传递实现了高效的逐点消融和个性化的病灶设置，” Field PULSE 的首席研究员、纽约西奈山医院的心电生理学家 Vivek Y. Reddy 博士说。“这种方法保留了医生对聚焦消融的灵活性，同时提供了与脉冲场技术相关的程序效率。”</p>
</div><p><strong>Study Highlights</strong></p>
<div class="lb-trans"><p><strong>研究亮点</strong></p>
</div><ul>
<li><strong>Instantaneous energy delivery:</strong> Lesions created in less than 200 milliseconds, enabling rapid point-by-point ablation</li>
<li><strong>Procedural efficiency:</strong> Median bilateral pulmonary vein isolation (PVI) time of 12.5 minutes, with the fastest case completed in 7.7 minutes</li>
<li><strong>PVI durability:</strong> Remapping demonstrated progressive improvement in PVI durability with the optimized waveform</li>
</ul>
<div class="lb-trans"><ul>
<li><strong>瞬时能量传递：</strong> 病灶在不到 200 毫秒内创建，实现快速逐点消融</li>
<li><strong>程序效率：</strong> 双侧肺静脉隔离（PVI）中位时间为 12.5 分钟，最快病例在 7.7 分钟内完成</li>
<li><strong>PVI 耐久性：</strong> 重新映射显示优化波形下 PVI 耐久性逐步改善</li>
</ul>
</div><ul>
<li><strong>By vein:</strong> 94.2%
<ul>
<li><strong>By patient:</strong> 84.6%</li>
</ul>
</li>
</ul>
<div class="lb-trans"><ul>
<li><strong>按静脉计算：</strong> 94.2%
<ul>
<li><strong>按患者计算：</strong> 84.6%</li>
</ul>
</li>
</ul>
</div><ul>
<li><strong>Safety outcomes:</strong></li>
</ul>
<div class="lb-trans"><ul>
<li><strong>安全结果：</strong></li>
</ul>
</div><ul>
<li>No device-related serious adverse events
<ul>
<li>No acute kidney injury, reported phrenic nerve palsy or clinically relevant hemolysis</li>
<li>Among patients evaluated by brain MRI (n=14), no silent cerebral lesions (DWI+/FLAIR+) were observed</li>
</ul>
</li>
</ul>
<div class="lb-trans"><ul>
<li>无设备相关的严重不良事件
<ul>
<li>无急性肾损伤、报告的膈神经麻痹或临床相关的溶血</li>
<li>在接受脑 MRI 评估的患者中（n=14），未观察到无症状脑病灶（DWI+/FLAIR+）</li>
</ul>
</li>
</ul>
</div><p>These findings extend Field Medical's body of clinical evidence of its high-voltage focal PFA approach beyond ventricular arrhythmias and into the development of therapy for atrial fibrillation (AF). Together with previously reported six-month first-in-human ventricular tachycardia (VT) data, the results support the emergence of a versatile ablation platform for all chambers of the heart, designed to enable focal PFA across atrial and ventricular substrates while preserving procedural efficiency.</p>
<div class="lb-trans"><p>这些发现扩展了 Field Medical 在高压聚焦 PFA 方法方面的临床证据，超越了心室心律失常，进入了房颤（AF）治疗的发展。结合之前报告的六个月首个人体心室心动过速（VT）数据，这些结果支持了一个多功能消融平台的出现，旨在实现心房和心室基质的聚焦 PFA，同时保持程序效率。</p>
</div><p>&#34;The Field PULSE results reinforce our approach of deliberately architecting focal PFA to address the fundamental limitations of existing methods, then validating its application through data,&#34; said Steven Mickelsen, M.D., founder and chief technology officer of Field Medical. &#34;By delivering each ablation point in a fraction of a second, we reduce dependence on prolonged catheter stability, limit the impact of cardiac motion and establish a platform approach for treating complex arrhythmias.&#34;</p>
<div class="lb-trans"><p>“Field PULSE 的结果强化了我们有意设计聚焦 PFA 以解决现有方法的基本局限性，然后通过数据验证其应用的思路，” Field Medical 的创始人兼首席技术官 Steven Mickelsen 博士说。“通过在瞬间传递每个消融点，我们减少了对长时间导管稳定性的依赖，限制了心脏运动的影响，并建立了治疗复杂心律失常的平台方法。”</p>
</div><p>The Field PULSE data were presented during the Late Breaking Clinical Trials Session I at AF Symposium 2026. Field Medical will be featured on Friday, February 6, from 7:30–8:30 a.m. during a scientific session on the biophysics of PFA for AF, including a presentation titled <em>Maximizing Lesion Depth Using High Voltage PFA Waveform</em> by Kenneth Ellenbogen, M.D., and during Case Transmission Session 6 on Saturday, February 7, from 7:30–9:30 a.m., highlighting <em>AF Ablation Using a High-Voltage Field Medical PFA Catheter</em>, presented by Vivek Reddy, M.D., using the FieldForce Ablation System and FieldForce Ablation Catheter.</p>
<div class="lb-trans"><p>Field PULSE 数据在 2026 年 AF 研讨会的最新临床试验会议 I 上进行了展示。Field Medical 将在 2 月 6 日星期五上午 7:30 至 8:30 的科学会议上介绍脉冲场消融（PFA）在房颤中的生物物理学，包括 Kenneth Ellenbogen 博士的题为《利用高压 PFA 波形最大化病灶深度》的演讲，并在 2 月 7 日星期六上午 7:30 至 9:30 的病例传输会议 6 上，突出 Vivek Reddy 博士使用 FieldForce 消融系统和 FieldForce 消融导管进行的《使用高压 Field Medical PFA 导管进行房颤消融》的演讲。</p>
</div><p><strong>About FieldForce™ Ablation System</strong> The FieldForce Ablation System is a focal, contact-sensing PFA system built on proprietary FieldBending™ technology to deliver targeted, high-intensity electric fields using a novel pulsed energy delivery strategy. Designed to support both atrial and ventricular ablation, the system serves as a universal ablation platform for the heart and beyond. The FieldForce system is designed to enable targeted and tailored ablation treatment while platform features focus on procedural efficiency.</p>
<div class="lb-trans"><p><strong>关于 FieldForce™消融系统</strong> FieldForce 消融系统是一种聚焦的接触感应 PFA 系统，基于专有的 FieldBending™技术，旨在通过新颖的脉冲能量传递策略提供针对性的高强度电场。该系统旨在支持心房和心室消融，作为心脏及其他部位的通用消融平台。FieldForce 系统旨在实现针对性和个性化的消融治疗，同时平台特性专注于程序效率。</p>
</div><p><strong>About Field Medical®, Inc.</strong></p>
<div class="lb-trans"><p><strong>关于 Field Medical®, Inc.</strong></p>
</div><p>Founded in 2022 by Steven Mickelsen, M.D., Field Medical is a clinical-stage medical technology company committed to advancing pulsed field ablation (PFA) solutions for complex cardiac arrhythmias. Its FieldForce Ablation System integrates a focal catheter design with proprietary FieldBending energy designed to safely deliver efficient, precise ablation with the goal of improving outcomes in ventricular and atrial arrhythmia treatment. In 2024, Field Medical earned Breakthrough Device Designation and gained entry into the FDA TAP Pilot Program for its ventricular tachycardia indication. In October 2025, the VCAS trial was published in <strong><em>Circulation</em></strong> <em>.</em></p>
<div class="lb-trans"><p>Field Medical 成立于 2022 年，由 Steven Mickelsen 博士创立，是一家临床阶段的医疗技术公司，致力于推进复杂心脏心律失常的脉冲场消融（PFA）解决方案。其 FieldForce 消融系统将聚焦导管设计与专有的 FieldBending 能量相结合，旨在安全高效地提供精确消融，以改善心室和心房心律失常治疗的结果。2024 年，Field Medical 获得突破性设备认证，并进入 FDA TAP 试点计划，针对其心室心动过速适应症。2025 年 10 月，VCAS 试验在 <strong><em>Circulation</em></strong> 上发表。</p>
</div><p>For more information, visit www.fieldmedicalinc.com and follow us on LinkedIn, X, and YouTube.</p>
<div class="lb-trans"><p>欲了解更多信息，请访问 www.fieldmedicalinc.com，并在 LinkedIn、X 和 YouTube 上关注我们。</p>
</div><p>The FieldForce™ Ablation System is an investigational device and is limited by federal (or United States) law to investigational use.</p>
<div class="lb-trans"><p>FieldForce™消融系统是一种研究性设备，受美国联邦法律限制，仅供研究使用。</p>
</div><p><strong>Media Contact</strong> Holly Windler</p>
<div class="lb-trans"><p><strong>媒体联系人</strong> Holly Windler</p>
</div><p>619.929.1275</p>
<div class="lb-trans"><p>619.929.1275</p>
</div><p>[email protected]</p>
<div class="lb-trans"><p>[email protected]</p>
</div><p>[email protected]</p>
<div class="lb-trans"><p>[email protected]</p>
</div><p>SOURCE Field Medical, Inc.</p>
<div class="lb-trans"><p>来源 Field Medical, Inc.</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwMjA1Jk5ld3NJdGVtSWQ9TEE4MDk2NyZUcmFuc21pc3Npb25fSWQ9MjAyNjAyMDUxNzQwUFJfTkVXU19VU1BSX19fX19MQTgwOTY3" alt="" original-src="https://rt.prnewswire.com/rt.gif?NewsItemId=LA80967&amp;Transmission_Id=202602051740PR_NEWS_USPR_____LA80967&amp;DateId=20260205"/></p>

17:40 ETField Medical 在 2026 年 AF 研讨会上展示了最新的 Field PULSE 试验数据